Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ombitasvir + paritaprevir + ritonavir + ribavirin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antiviral therapy used for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotypes 1 and 4. This regimen combines three direct-acting antivirals (ombitasvir, paritaprevir, ritonavir) with ribavirin. Ombitasvir is an HCV NS5A inhibitor that prevents viral replication, paritaprevir is a protease inhibitor that decreases viral load, ritonavir serves as a pharmacokinetic enhancer to boost paritaprevir levels, and ribavirin is an antiviral medication that works in combination with the other drugs. The combination has demonstrated high cure rates (91-100%) in clinical trials.
- Brand names
- QurevoTechnivieRebetolCopegus
- Other names
- ombitasvir + paritaprevir + ritonavir + ribavirinombitasvir/paritaprevir/ritonavir plus ribavirin
02
Targets
CYP3A4 (Cytochrome P450 3A4)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))vRNA (Coronavirus viral RNA)
Beyond the preview
Go deeper on ombitasvir + paritaprevir + ritonavir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ombitasvir + paritaprevir + ritonavir + ribavirin.